Yanyan Xing

Yanyan Xing has a solid background in scientific research, with experience in various roles and organizations. They started their career as a Graduate Student at Jinan University in 2011, where they participated in projects exploring the effects of Morphine in the development of HIV dementia. They also helped establish rodent dementia models and worked on projects using curcumin to treat HAND.

In 2014, Yanyan Xing joined Indiana University–Purdue University Indianapolis as a Graduate Student. Here, they led NIH projects and projects funded by the Bill & Melinda Gates Foundation, studying the role of matrix metalloproteinases (MMPs) in HIV-associated neurocognitive disorders (HAND). They also established neurological research platforms and implemented techniques such as in vitro 3D blood-brain barrier models and proteomics.

In 2018, Yanyan Xing became a Postdoctoral Researcher at the Georgia Institute of Technology. During this time, they led multiple projects funded by NIH and Pfizer Inc. focused on determining the role of Mas-related G-coupled protein receptors (Mrgprs) in mediating skin diseases and asthma-induced airway hyperresponsiveness. They also set up a FACS sorting pipeline for primary neurons of transgenic mouse models and identified new markers in sensory neurons during asthma-induced airway hyperresponsiveness and dermatitis.

Most recently, Yanyan Xing joined Empress Therapeutics as a Scientist in 2023, where they continue their scientific research and contributions.

Yanyan Xing pursued a Joint Ph.D. program in Microbiology and Immunology from 2014 to 2017 at Indiana University–Purdue University Indianapolis. Prior to that, from 2011 to 2017, they obtained a Doctor of Medicine (MD) degree with a specialization in Pathophysiology from Jinan University. Currently, they are pursuing a Master's degree in Computer Science at Georgia Institute of Technology, starting in 2020.